Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $37.00

Maze Therapeutics (NASDAQ:MAZE) had its price objective upped by JPMorgan Chase & Co. from $27.00 to $37.00 in a report published on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts also recently issued reports about the stock. BTIG Research increased their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Guggenheim increased their price target on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Wedbush assumed coverage on Maze Therapeutics in a report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 price objective for the company. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Maze Therapeutics in a research report on Thursday, September 18th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $33.83.

Maze Therapeutics Stock Performance

Shares of NASDAQ MAZE opened at $25.81 on Monday. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $28.37. The business has a 50 day moving average price of $17.57 and a two-hundred day moving average price of $13.45.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Insider Activity at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Institutional Investors Weigh In On Maze Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in shares of Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after purchasing an additional 1,455 shares during the period. CWM LLC bought a new position in Maze Therapeutics in the 2nd quarter worth approximately $28,000. New York State Common Retirement Fund acquired a new stake in Maze Therapeutics in the 1st quarter valued at approximately $25,000. Legal & General Group Plc raised its stake in Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after acquiring an additional 3,371 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Maze Therapeutics by 452.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock worth $57,000 after acquiring an additional 3,774 shares during the period.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.